GBA1 and Parkinson disease: Using high-throughput screening, two GBA1 chaperone compounds, NCGC607 and NCGC758, have been tested in iPSC-derived dopaminergic neurons from PD patients and induced improved GCase activity as well as decreased levels of α-syn and GCase substrates [355,356].